DUBLIN–(BUSINESS WIRE)–The “Global Oncolytic Virus Therapies Market: Focus on Commercialized Therapies, Pipeline Therapies, Type of Virus, Application, Region (15 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.
Global Oncolytic Virus Therapies Market to Reach $962.0 Million by 2030
Oncolytic virus therapies to be one of the most rapidly evolving technologies, and the global market is predicted to grow at a CAGR of 26.28% over the forecast period 2020-2030.
Market Overview
Oncolytic virus therapies are overlapping biomedical research fields with similar therapeutic goals, which target DNA or RNA inside or outside the body. These therapies aim at modifying genetic material for the treatment of a disease. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells. Oncolytic virus therapy is “a novel approach to treat, cure, or ultimately prevent disease by changing the expression of a person’s genes”. Oncolytic virotherapy is a form of gene therapy that used nature’s material (virus) to find and destroy malignant cells.
Factors fueling the growth of the market include prevalence of cancer, rising number of clinical trials, boosting research funding, and adoption of inorganic growth. Despite rapid advanced industry growth, there are several key issues that need to be addressed to facilitate future growth such as the relatively high total costs of therapies and lacking therapy-specific assay. Further, some of the opportunities such as clinical pipeline of therapies provide growth to the market.
Within the research report, the market has been segmented on the basis of commercialized therapies, pipeline therapies, type of virus, application, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the cases of cancer on the global level has created a buzz among companies to invest in the therapeutics of advanced technologies. Due to a large number of pipeline therapies and intense market penetration, oncolytic virus therapies have been pioneers in the therapeutic field and have significant competitors in this market.
Based on region, North America held the largest share in 2020, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Europe and the Asia-Pacific are anticipated to grow at the fastest CAGR during the forecast period.
Key Topics Covered:
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Oncolytic Virus Therapies Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market
5 Industry Insights
5.1 Overview
5.2 Regulatory Scenario
5.3 Legal Requirements and Framework in the U.S
5.3.1 Clinical Trial Authorization
5.3.2 U.S. FDA Guidelines for BLA Submission
5.4 Legal Requirements and Framework in Europe
5.4.1 EMA Biologics License Application Process
5.4.2 Centralized Procedure
5.4.3 Decentralized Procedure
5.4.4 Mutual-Recognition Procedure
5.5 Legal Requirements and Framework in Asia-Pacific
5.5.1 China
5.5.2 Japan
5.6 Expedited Regulatory Designations Around the World
5.7 Reimbursement Scenario
5.8 Patent Analysis
5.8.1 Patent Filing Trend
6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Increasing Incidence of Cancer
6.3.2 Rising Number of Clinical Trials
6.3.3 Increasing Research Funding from National Cancer Institute
6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market
6.4 Market Restrains
6.4.1 High Cost of Therapy
6.4.2 Lack of Therapy-Specific Assays
6.5 Market Opportunities
6.5.1 Opportunities in the Emerging Economies
6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies
7 Competitive Landscape
7.1 Synergistic Activities
7.2 Business Expansion Activities and Others
7.3 Product Launches and Product Updates
7.4 Mergers and Acquisitions
7.5 Market Share Analysis
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Commercialized Therapy)
8 Oncolytic Virus Therapies: Epidemiology Analysis
9 Global Oncolytic Virus Therapies Market (by Commercialized Therapies), $Million, 2019-2030
9.1 Overview
9.2 Imlygic
9.3 Oncorine
9.4 RIGVIR
10 Global Oncolytic Virus Therapies Market (by Pipeline Therapies), $Million, 2019-2030
10.1 Overview
10.2 Phase I
10.3 Phase II
10.4 Phase III
10.5 Phase IV
11 Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
11.1 Overview
11.2 Genetically Engineered Oncolytic Virus
11.2.1 Herpes Simplex Virus (HSV)
11.2.2 Adenovirus
11.2.3 Vaccinia Virus
11.3 Oncolytic Wild-Type Virus
11.3.1 Reovirus (Respiratory Enteric Orphan Virus)
11.3.2 Newcastle Disease Virus (NDV)
11.3.3 Vesicular Stomatitis Virus (VSV)
12 Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
12.1 Overview
12.2 Solid Tumor
12.2.1 Breast Cancer
12.2.2 Prostate Cancer
12.2.3 Lung Cancer
12.2.4 Glioblastoma
12.2.5 Melanoma
12.2.6 Other Applications
12.3 Hematological Malignancies
12.3.1 Lymphoma
12.3.2 Leukemia
12.3.3 Myeloma
13 Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
13.1 Overview
14 Company Profiles
- Amgen Inc.
- DAIICHI SANKYO COMPANY, LIMITED
- DNAtrix
- Genelux
- Oncolytics Biotech, Inc.
- PsiOxus Therapeutics
- RIGVIR Ltd.
- Shanghai Sunway Biotech Co., Ltd.,
- SillaJen, Inc.
- Sorrento Therapeutics, Inc.
- Takara Bio Inc.
- Transgene sa
- VCNBiosciences
- ViroCure
- Viralytics Ltd. (Merck & Co., Inc.)
For more information about this report visit https://www.researchandmarkets.com/r/ximwga
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900